Pharmacology & Therapeutics

Article	Citations
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future	331
Tumor microenvironment as a therapeutic target in cancer	317
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections	297
Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony	228
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients	188
Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?	184
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms	181
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges	171
Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders	169
Lactate/GPR81 signaling and proton motive force in cancer: Role in angiogenesis, immune escape, nutrition, and Warburg phenomenon	142
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development	122
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions	117
ATM in DNA repair in cancer	116
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders	115
The origin of NMDA receptor hypofunction in schizophrenia	109
The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species	105
The birth of artemisinin	103
Resolution of inflammation: An organizing principle in biology and medicine	101
Cancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancer	98
TRPC channels: Structure, function, regulation and recent advances in small molecular probes	96
Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans	92
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery	91
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies	90
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression	89
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer	88

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?	85
Circulating tumor DNA as an early cancer detection tool	84
Therapeutic potential of resveratrol against emerging respiratory viral infections	84
An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy	82
The past, present and future perspectives of matrix metalloproteinase inhibitors	82
Carcinogenesis: Failure of resolution of inflammation?	81
Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential	80
Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment	79
Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target	78
Physiologically-based pharmacokinetic models for children: Starting to reach maturation?	74
Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases	74
Targeting autophagy in ischemic stroke: From molecular mechanisms to clinical therapeutics	74
The therapeutic potential of second and third generation CB1R antagonists	73
Therapeutic targets in lung tissue remodelling and fibrosis	72
Traditional application and modern pharmacological research of Artemisia annua L.	71
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders	71
The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease	71
Drug repurposing for COVID-19: Approaches, challenges and promising candidates	70
Dopamine outside the brain: The eye, cardiovascular system and endocrine pancreas	68
Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions	68
Advances in pathogenesis and therapeutic strategies for osteoporosis	67
Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis	66
Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy	65
Immunotherapy in sepsis - brake or accelerate?	64
Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases	63
Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective	63
Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma	61
The strategies and techniques of drug discovery from natural products	60
Programming inflammatory cell death for therapy	59
Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining	59
Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors	59
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint	58
A hypothesis of monoamine (5-HT) – Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery	58
Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis	58
The Role of non-coding RNAs in colorectal cancer, with a focus on its autophagy	57
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms	57
Drugging K-RasG12C through covalent inhibitors: Mission possible?	57
Biased GPCR signaling: Possible mechanisms and inherent limitations	57
Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases	56
A decade of cell death studies: Breathing new life into necroptosis	55
Role of the ERO1-PDI interaction in oxidative protein folding and disease	55
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders	55
Chinmedomics, a new strategy for evaluating the therapeutic efficacy of herbal medicines	55
Polyphenols and neuroprotection: Therapeutic implications for cognitive decline	54
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	54
Role of Rad51 and DNA repair in cancer: A molecular perspective	54
Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration	53
TP53 in bone and soft tissue sarcomas	53
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy	53
Adolescent neurodevelopment and substance use: Receptor expression and behavioral consequences	52

Targeting opioid dysregulation in depression for the development of novel therapeutics	52
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics	52
Circular RNAs are a novel type of non-coding RNAs in ROS regulation, cardiovascular metabolic inflammations and cancers	51
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges	51
G-quadruplex-based aptamers targeting human thrombin: Discovery, chemical modifications and antithrombotic effects	50
The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy	48
Metal-dependent Ser/Thr protein phosphatase PPM family: Evolution, structures, diseases and inhibitors	48
Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy	47
Current developments of targeting the p53 signaling pathway for cancer treatment	47
Kynurenine emerges from the shadows – Current knowledge on its fate and function	47
Targeting post-translational histone modifying enzymes in glioblastoma	46
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders	46
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential	45
Sirtuins' control of autophagy and mitophagy in cancer	45
Tumor organoid models in precision medicine and investigating cancer-stromal interactions	44
Pharmacology and perspectives in erectile dysfunction in man	44
Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences	44
Autophagy as a novel therapeutic target in vascular calcification	44
Role of inflammatory chemokines in hypertension	44
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer	43
Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?	43
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights	43
Updates on community acquired pneumonia management in the ICU	43
Effects of local anesthetics on cancer cells	43
Aldehyde oxidase and its role as a drug metabolizing enzyme	42
A deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer	42
Molecular mechanisms of cereblon-based drugs	42
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19	41
The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention	41
Extracellular vesicles in cancer diagnostics and therapeutics	39
TGFβ-Directed Therapeutics: 2020	39
Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system	39
Endozepines and their receptors: Structure, functions and pathophysiological significance	38
Targeting BET bromodomain proteins in cancer: The example of lymphomas	38
FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention	38
Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy	38
Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain	38
New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma	38
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications	38
Myeloperoxidase: Mechanisms, reactions and inhibition as a therapeutic strategy in inflammatory diseases	38
Particulate matter air pollutants and cardiovascular disease: Strategies for intervention	37
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials	37
Molecular imaging of inflammation - Current and emerging technologies for diagnosis and treatment	36
Evidence-based pharmacological treatment options for ADHD in children and adolescents	36
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	36
Cognitive dysfunction in major depression: From assessment to novel therapies	36
Targeting the NLRP3 inflammasome in cardiovascular diseases	36
Live cell imaging of signaling and metabolic activities	35
Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing	35
An overview on anti-tubulin agents for the treatment of lymphoma patients	35
Chronopharmacological strategies focused on chrono-drug discovery	35
Advances in the research on the targets of anti-malaria actions of artemisinin	35
Metabolomics, metabolic flux analysis and cancer pharmacology	35
Long non-coding RNAs as new regulators of cardiac electrophysiology and arrhythmias: Molecular mechanisms, therapeutic implications and challenges	34
Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease – frontiers and horizons	34
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities	34
Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness	34
Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention	34
Recent advances in genome editing of stem cells for drug discovery and therapeutic application	34
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system	33
Cyclodextrins: Potential therapeutics against atherosclerosis	33
Current state and future perspective of cardiovascular medicines derived from natural products	33
Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy	33
Genotoxic therapy and resistance mechanism in gliomas	33
Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies	33
Keep an eye on adenosine: Its role in retinal inflammation	33
Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications	32
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases	32
GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors	32
Medulloblastoma: Molecular understanding, treatment evolution, and new developments	32
Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments	32
Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics	32
Immune activities of polysaccharides isolated from Lycium barbarum L. What do we know so far?	32
FGFR4: A promising therapeutic target for breast cancer and other solid tumors	32
Stepping forward in antibody-drug conjugate development	32
A review on the pathophysiology of asthma remission	31
Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination	31
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	31
Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease	31
Inhibition of serotonin synthesis: A novel therapeutic paradigm	31

Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	31
Understanding the mechanism of radiation induced fibrosis and therapy options	31
In cancer, all roads lead to NADPH	30
Targeting the crosstalk between canonical Wnt/β-catenin and inflammatory signaling cascades: A novel strategy for cancer prevention and therapy	30
Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside	30
Myeloperoxidase: A versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease	30
Antifungal effects of statins	30
Toxicology of flavoring- and cannabis-containing e-liquids used in electronic delivery systems	30
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	30
The role of CD71+ erythroid cells in the regulation of the immune response	29
Glycoprotein VI - novel target in antiplatelet medication	29
Pulmonary arterial hypertension specific therapy: The old and the new	29
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality	29
Long noncoding RNA loss in immune suppression in cancer	29
Clinical therapies and nano drug delivery systems for urinary bladder cancer	29
CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design	29
The roles of non-coding RNAs in vascular calcification and opportunities as therapeutic targets	29
Antimicrobial peptides – Unleashing their therapeutic potential using nanotechnology	29
Targeting epigenetic machinery: Emerging novel allosteric inhibitors	29
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target	29
NF-κB signaling promotes castration-resistant prostate cancer initiation and progression	28
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	28
Recent advances in bone-targeted therapy	28
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor	28
Pharmacological targets of metabolism in disease: Opportunities from macrophages	28
SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin	28
TSLP as druggable target – a silver-lining for atopic diseases?	28
Dietary nutrition for neurological disease therapy: Current status and future directions	27
Rational targeting of immunosuppressive neutrophils in cancer	27
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance	27
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options	27
Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis	27
Cannabinoids as therapeutics for PTSD	27
Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges	27